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Abstract 17 
Chronic kidney disease is associated with a unique cardiomyopathy, characterised by a 18 
combination of structural and cellular remodelling, and an enhanced susceptibility to 19 
ischaemia-reperfusion injury.  This may represent dysfunction of the reperfusion injury 20 
salvage kinase pathway, due to insulin resistance. 21 
Aims: The susceptibility of the uraemic heart to ischaemia-reperfusion injury and the 22 
cardioprotective effects of insulin and rosiglitazone were investigated.   23 
Methods and Results: Uraemia was induced in Sprague-Dawley rats by subtotal 24 
nephrectomy.  Functional recovery from ischaemia was investigated in vitro in control and 25 
uraemic hearts ±insulin ±rosiglitazone.  The response of myocardial oxidative metabolism to 26 
insulin was determined by 13C NMR spectroscopy.  Activation of reperfusion injury salvage 27 
kinase pathway intermediates (Akt and GSK3β) were assessed by SDS-PAGE and 28 
immuno-precipitation.  Insulin improved post-ischaemic rate pressure product in control but 29 
not uraemic hearts, (recovered rate pressure product (%), control 59.6±10.7 vs 88.9±8.5,  30 
p<0.05; uraemic 19.3±4.6 vs 28.5±10.4, p=ns).  Rosiglitazone resensitised uraemic hearts to 31 
insulin-mediated cardio-protection (recovered rate pressure product (%) 12.7±7.0 vs. 32 
61.8±15.9, p<0.05).  Myocardial carbohydrate metabolism remained responsive to insulin in 33 
uraemic hearts.  Uraemia was associated with increased phosphorylation of Akt (1.00±0.08 34 
vs. 1.31±0.11, p<0.05) in normoxia, but no change in post-ischaemic phosphorylation of Akt 35 
or GSK3β.  Akt2 isoform expression was decreased post-ischaemia in uraemic hearts 36 
(p<0.05). 37 
Conclusion: Uraemia is associated with enhanced susceptibility to ischaemia-reperfusion 38 
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injury and a loss of insulin-mediated cardio-protection, which can be restored by 39 
administration of rosiglitazone.  Altered Akt2 expression in uraemic hearts post 40 
ischaemia-reperfusion and impaired activation of reperfusion injury salvage kinase pathway 41 
may underlie these findings. 42 
Key Words 43 
Chronic kidney disease; ischaemia reperfusion injury; RISK pathway 44 
45 
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Introduction 46 
Chronic kidney disease (CKD) is an independent risk factor for cardiovascular mortality. (85)  47 
Although ‘traditional’ cardiovascular risk factors identify high risk populations, multiple 48 
‘non-traditional’ risk factors which may be specific to CKD have also been identified. (71)  49 
Experimental and clinical investigations have provided evidence for unique properties of the 50 
uraemic heart at both cellular and structural levels which amount to a distinct uraemic 51 
cardiomyopathy (UCM). (3)  An emerging feature of UCM is an enhanced susceptibility of 52 
the heart to ischaemia-reperfusion injury (IRI). (23) 53 
IRI is a complex process in which the final common pathway for cellular damage is opening 54 
of the mitochondrial permeability transition pore (mPTP), (31) itself the focus of an 55 
endogenous protective cascade, termed the reperfusion injury salvage kinase (RISK) 56 
pathway. (33)  Diverse strategies and ligands, including insulin, have been identified which 57 
activate this cascade and confer significant cardio-protection in experimental models. (33)  58 
In addition, small clinical trials and retrospective analyses of larger clinical studies suggest 59 
favourable outcomes when RISK activating interventions are given early. (4,59,60) 60 
Insulin resistance remains an independent risk factor for cardiac death in CKD stages 3-5 and 61 
end stage renal failure. (6,75,82)  The insulin signalling cascade converges on the RISK 62 
pathway at protein kinase Akt (also known as protein kinase B), and insulin administration is 63 
cardioprotective in non-uraemic experimental models of IRI. (37)  Both experimental and 64 
clinical CKD have been associated with insulin resistance due to a post-receptor defect in 65 
skeletal muscle, (46) raising the possibility of impaired activation of the RISK pathway as a 66 
mechanism to explain the enhanced susceptibility to IRI.  Experimental uraemia is 67 
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associated with increased chronic Akt phosphorylation and activation, (49) which has been 68 
experimentally demonstrated to inhibit RISK pathway cardio-protection in non-hypertrophied 69 
hearts. (56) 70 
Thiazolidiones (TZDs) enhance glycaemic control in insulin resistance states, although their 71 
widespread clinical use is limited by adverse effects on heart failure. (18,58,77)  However, 72 
experimentally pre-treatment with thiazolidiones offers cardioprotection in models of IRI. 73 
(48,89)  In particular, rosiglitazone exerts cardioprotective effects in other non-uraemic but 74 
insulin resistant states, (90) an action mediated, at least in part, through the Akt and the RISK 75 
pathway, (89) via cardiac peroxisome proliferator-activated receptor γ (PPARγ). (87) 76 
There is a great clinical need to better understand the pathophysiology of UCM.  Although 77 
CKD is a chronically progressive condition, the risk of progression to end stage renal failure 78 
is overshadowed at all stages by a greater risk of death from cardiovascular causes. (32,42)  79 
This excessive cardiovascular risk continues after the initiation of renal replacement therapy 80 
and half of all deaths in the dialysis population are a result of cardiovascular events. (25,47)  81 
Further, in the haemodialysis population, there is increasing evidence that haemodialysis 82 
itself results in repeated cardiac IRI episodes that adversely affect cardiac function and 83 
prognosis. (10) 84 
To date there are no data on the functional consequences of IRI, or the efficacy of the 85 
cardio-protective RISK pathway in experimental uraemia.  Using the surgical remnant 86 
kidney model of chronic uraemia, this study investigated the hypothesis that the myocardial 87 
insulin resistance evident in UCM enhances the susceptibility of the uraemic heart to 88 
ischaemic reperfusion injury through impaired response of the RISK pathway.  Further, we 89 
tested the hypothesis that pre-treatment with the insulin sensitising agent, rosiglitazone, 90 
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would improve cardioprotection in UCM. 91 
Methods 92 
Experimental model of uraemia 93 
All animal experiments conformed to the UK Animals (Scientific Procedures) Act 1986 and 94 
the Guide for the Care and Use of Laboratory Animals published by the US National 95 
Institutes of Health (NIH Publication No. 85-23, revised 1985).  Uraemia was induced in 96 
male Sprague-Dawley rats (approximately 250g) (Charles River, Sussex, UK), via a 97 
one-stage 5/6th nephrectomy as described previously. (79)  Briefly, animals were 98 
anaesthetised using a mixture of isoflurane in oxygen (2.5% in 1L), a laparotomy was 99 
performed, the left kidney exposed, and at least two-thirds removed.  This was immediately 100 
followed by a total right nephrectomy.  Care was taken to ensure no damage was done to the 101 
adrenal glands.  For control animals, a sham operation was performed whereby both kidneys 102 
were decapsulated and replaced intact. 103 
Animals were maintained for 12 weeks post induction of uraemia, housed individually and 104 
pair-fed with control animals. Water was available ad libitum. Cardiac hypertrophy was 105 
assessed at the time of sacrifice by determining wet heart weight/tibia length (HW:TL). 106 
Isolated heart perfusion 107 
Animals were fasted for 12 hours, anaesthetised with sodium thiopentone (100 mg/Kg body 108 
weight) and the hearts excised.  Hearts were perfused via the aorta in an isovolumic 109 
Langendorff mode, as described previously, (79) using Krebs-Henseleit buffer containing 3% 110 
fatty acid free Bovine serum albumin (BSA) and the following components (mM) NaCl 111 
(118.5), NaHCO3 (25), KCl (4.8), KH2PO4 (1.2), MgSO4 (1.2), CaCl2 (1.25-2.5), glucose (5), 112 
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sodium pyruvate (0.1), sodium lactate (1), sodium palmitate (0.3), glutamine (0.5) ± 0.1 113 
mU/ml insulin.  The buffer was gassed with 95% O2, 5% CO2 and maintained at 37°C. 114 
Cardiac function was recorded continuously via a fluid filled balloon (inserted into the left 115 
ventricle) and a physiological pressure transducer (SensoNor, Norway) connected to a bridge 116 
amplifier and Powerlab 4/30 (20).  Data were recorded using Chart 5.5 software (AD 117 
Instruments, Hastings UK).  The end diastolic pressure (EDP) was set to 5-7 mmHg by 118 
adjusting the balloon volume and hearts were paced at 300 bpm.  Effluent samples were 119 
collected and oxygen content measured using a blood gas analyser (ABL77 Radiometer, 120 
Copenhagen, Denmark).  Oxygen consumption (MVO2) was calculated as the product of 121 
arterio-venous oxygen content difference and coronary flow rate (ml/min) normalised to wet 122 
heart weight. (57)  Heart rate (HR), left ventricular peak systolic and end diastolic pressures 123 
(PSP and EDP), and rate of change of left ventricular pressure (+/-dP/dt) were recorded.  As 124 
a measure of cardiac work, rate pressure product (RPP) was calculated from (PSP-EDP) × 125 
HR and the ratio RPP/MVO2 used as an indicator of cardiac efficiency. 126 
Steady state perfusion for assessment of myocardial metabolism. 127 
After a 20-minute equilibration period, the perfusion medium was switched to an identical 128 
buffer replacing unlabelled substrates with 1-13C labelled glucose and U-13C palmitate for 45 129 
minutes. Hearts were then freeze-clamped using Wollenberger tongs and extracted using 6% 130 
perchloric acid for Nuclear Magnetic Resonance (NMR) spectroscopy. (72) 131 
Induction of ischaemia reperfusion injury. 132 
After a 20-minute equilibration period or normoxic perfusion with insulin free buffer, hearts 133 
were immersed in perfusion buffer at 37oC and perfusion ceased (warm total global 134 
ischaemia) for 25 minutes.  On reperfusion, the ventricular balloon was deflated for 5 135 
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minutes to minimise the ‘no re-flow’ phenomena. (27)  The ventricular balloon as then 136 
re-inflated to produce an EDP of 5-7mmHg and indices of cardiac function measured as 137 
above for 25 minutes. 138 
Insulin (0.1 mU/ml) was added to the reperfusion buffer immediately on reperfusion if 139 
indicated by experimental group. 140 
13C- NMR spectroscopy 141 
High-resolution 1H decoupled 13C NMR spectra were collected at 101 MHz using an 11.7 142 
Tesla ultra- shielded superconducting vertical wide bore magnet and 5mm broadband probe 143 
interfaced with a Bruker spectrometer.  Free induction decays (FIDs) were acquired over 144 
32000 scans with a 90° pulse (9.95 us pulse duration and 1 s inter-pulse delay) and fourier 145 
transformed for analysis using Bruker Topspin (1.3) software.  The relative contributions of 146 
glucose and palmitate to oxidative metabolism were determined using the TCAcalc program 147 
provided by Dr Mark Jeffrey (University of Texas, Southwestern Medical centre, TX). (79) 148 
Haematocrit and serum metabolite analysis 149 
Fasting venous tail blood samples for analysis of serum insulin concentration were obtained 150 
prior to terminal anaesthetisation, separated by centrifugation (3000g 4oC) and analysed 151 
using an ultra-sensitive rat specific insulin ELISA kit as per the manufacturer’s instructions 152 
(Mercodi, Sweden).  Immediately after excision of the heart, blood samples were collected 153 
from the chest cavity into heparinised syringes for determination of haematocrit using the 154 
blood gas analyser or centrifuged at 4000g for 10 minutes at 4°C.  Serum was removed and 155 
stored at -20°C for metabolite analysis. Serum urea and creatinine were analysed at the 156 
Clinical Biochemistry Department, Hull Royal Infirmary, Hull and East Yorkshire Hospitals 157 
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NHS Trust, UK.  HOMA-IR has been used previously to assess insulin resistance in rat 158 
models (1,15) and was calculated by the following equation: HOMA-IR=[fasting serum 159 
glucose]*[fasting serum insulin]/22.5 160 
Protein expression 161 
Expression of total Akt, pAkt, GSK3β, phospho GSK3β (pGSK3β), ANP and β-Actin in 162 
uraemic and control hearts were determined by western blotting as described previously. (79)  163 
Briefly, samples containing 20μg protein were separated on 10% sodium dodecyl sulphate 164 
polyacrylamide gel electrophoresis (SDS PAGE) and transferred onto nitrocellulose 165 
membranes.  Membranes were incubated with primary antibodies (rabbit monoclonal 166 
anti-Akt, anti-pAkt(ser473), anti- GSK3β anti-pGSK3β(ser9) and anti-β-Actin at 1:1000 167 
dilution, New England Biolabs, USA, rabbit polyclonal anti-ANP, Santa Cruz Biotech USA) 168 
followed by secondary antibody (1:2000 dilution goat anti-rabbit, Santa Cruz Biotech, USA).  169 
Protein bands were visualised using enhanced chemiluminescence (ECL) (Amersham, 170 
Uppsala, Sweden) and quantified using scanning densitometry and ImageJ software.  171 
β-Actin was used as the loading control. 172 
Expression of total and phosphorylated Akt1 and Akt2 were determined by first 173 
immuno-precipitating the isomer of interest from a crude extract using anti-Akt isomer 174 
monoclonal antibodies (1:50, anti-Akt1 and anti-Akt2, New England Biolabs, USA) with 175 
agarose beads, before separation of proteins by 10% SDS-PAGE and Western blotting with 176 
anti-Akt and anti-pAkt(ser473) as above. 177 
Rosiglitazone administration 178 
Rosiglitazone (Avandiatm, Glaxo-Smith-Kline, UK) was administered to animals by oral 179 
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gavage at a dose of 3mg/kg/day for eight days prior to experimentation as described in (91).  180 
Treatment control animals received identical volumes (by weight) of vehicle (PEG). 181 
Experimental groups were control (C) vs. uraemic (U), rosiglitazone untreated (-R) and 182 
treated (+R), and non-insulin (-I) and insulin (+I) treated, resulting in eight groups in total. 183 
Statistical analysis 184 
Results are expressed as mean ± SEM. Statistical significance was determined using an 185 
unpaired t test (for single mean comparisons) or two-way ANOVA when testing 2 186 
independent variables (using the Scheffe post-hoc test). Pearsons analysis was used to 187 
determine the significance of bi-variate correlations. Statistical analysis was performed using 188 
SPSS software (16.0) and level of significance was set at p less than 0.05. 189 
Results 190 
Uraemia is associated with compensated ventricular hypertrophy independently of cardiac or 191 
systemic insulin resistance.  The magnitude of elevation of both serum creatinine and urea in 192 
the uraemic group at 12 weeks were comparable with previous studies. (1,66) Uraemia was 193 
associated with anaemia, but not with impaired growth (preserved tibia length) (table 1). 194 
Cardiac hypertrophy (determined by increased HW:TL) developed in uraemic animals (table  195 
1) and correlated with serum creatinine (HW:TL r=0.37, p<0.001).  However, there was no 196 
increase in percentage lung water and uraemic hearts exhibited no evidence of dysfunction 197 
with no change in rate pressure product (RPP), contractility (dP/dtmax), relaxation (dP/dtmin) 198 
or cardiac efficiency (table 2), findings consistent with compensated ventricular hypertrophy. 199 
Fasting serum glucose, free fatty acids, insulin concentrations and HOMA-IR did not differ 200 
between control and uraemic animals (table 1).  In fact there was a trend towards improved 201 
  11  
HOMA-IR scores in uraemic animals, providing little evidence of systemic insulin resistance 202 
in this model.  Furthermore, subsequent assessment of insulin mediated substrate utilisation 203 
in isolated hearts by 13C NMR spectroscopy, did not detect cardiac insulin resistance (table 204 
2).  Uraemia altered substrate utilisation in a manner consistent with our previous findings in 205 
this rat strain (79) and remained sensitive to insulin (table 2). 206 
Uraemia is associated with decreased functional recovery and a loss of insulin mediated 207 
cardio-protection after ischaemia reperfusion injury.  The effects of IRI were assessed 208 
during ex vivo cardiac perfusion.  Twenty-five minutes of total global ischaemia produced a 209 
significantly greater impairment of cardiac function in uraemic hearts (max recovered RPP 210 
(%) 59.6±10.7 vs. 19.3±4.6, n=10, p<0.05; figure 1) than in controls.  Furthermore, while 211 
insulin demonstrated a cardioprotective effect in control hearts (max recovered RPP (%) 212 
59.6±10.7 vs 88.9±8.5, n=10, p<0.05), consistent with other published studies 213 
(29,37,39,52,92), such an effect was not seen in uraemic hearts (max recovered RPP (%) 214 
19.3±4.6 vs 28.5±10.4, n=10, p=ns) (figure 1). 215 
Rosiglitazone therapy is associated with restoration of the cardioprotective effects of insulin 216 
in the uraemic heart.  The ability of the oral thiazolidione rosiglitazone to re-sensitise the 217 
uraemic heart to the protective effects of insulin was investigated in the uraemic model.  218 
Administration of rosiglitazone at a dose of 3mg/kg/day for 8 days had no effect on weight 219 
gain, tibia length, renal function, anaemia in either group (table 1).  Nor did it affect 220 
hypertrophy of the remnant kidney or heart in uraemic animals.  Overall, rosiglitazone 221 
reduced fasting glucose and insulin concentrations, and thus HOMA-IR (table 1), although 222 
this effect did not reach statistical significance in uraemic animals.  Rosiglitazone had little 223 
effect on serum fatty acid levels.  Baseline ex vivo cardiac function was also unaffected by 224 
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rosiglitazone administration (table 3). 225 
In control hearts rosiglitazone appeared to improve post IRI function, but did not modify the 226 
cardioprotective effect of insulin (figure 2 and table 4).  In uraemic hearts, however, an 227 
overall positive effect on cardiac recovery was associated with rosiglitazone treatment (figure 228 
3 and table 5).  The combination of rosiglitazone and insulin treatment was also linked with 229 
significant improvements in recovery of cardiac function, as evidenced by increased RPP, 230 
dP/dtmax,dP/dtmin, and was associated with greater recovery than either treatment alone. 231 
Uraemia is associated with altered activation of the common insulin signalling and RISK 232 
pathway intermediate Akt, but not the common intermediate GSK3β.  Protein expression in 233 
ventricular muscle (prior to ischaemia) of total Akt, phospho Akt, Akt1 and Akt2 isoforms, 234 
total GSK3β and phospho GSK3β was assessed by immuno-blotting and 235 
immuno-precipitation.  Ventricular  muscle phospho Akt was significantly increased in the 236 
uraemic hearts (relative optical density 1.00±0.08 vs. 1.3±0.11; n=12, p<0.05; figure 4), 237 
which was predominantly attributable to phosphorylation of Akt2 rather than Akt1 (figure 5).  238 
However, there was no change in phospho and total GSK3β associated with uraemia 239 
(pGSK3β 1.00±0.05 vs. 0.90±0.03, n=23, p=ns;  total GSK3β 1.00±0.03 vs. 0.88±0.06, 240 
n=23, p=ns). 241 
The presence of insulin at reperfusion was associated with an increase in both phospho Akt 242 
and phospho GSK3β independently of uraemia (Control: pAkt 1.00±0.6 vs. 17.4±3.5, n=12, 243 
p<0.05;  pGSK3β 1.0±0.1 vs. 2.5±0.3, n=12, p=ns;  Uraemic: pAkt 3.5±1.8 vs. 14.5±7.1, 244 
n=12, p<0.05;  pGSK3β 1.0±0.2 vs. 4.7±2.2, n=12, p<0.05).  Uraemia was not related to a 245 
change in post ischaemic Akt1 phosphorylation or expression, but both insulin and uraemia 246 
produced independent reductions in total Akt2 (tAkt2) expression post-IRI (figure 6). 247 
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Discussion 248 
UCM is characterised by increased susceptibility to IRI and a failure of insulin mediated 249 
cardio-protection - potential role for altered RISK pathway activation.  Uraemic hearts 250 
displayed significantly reduced functional recovery during reperfusion (figure 1).  These 251 
observations complement those of Dikow et al (22,23), who demonstrated increased infarct 252 
size following temporary occlusion of the left coronary artery in uraemic rats in vivo and are 253 
consistent with the clinical picture of adverse outcomes in patients with IHD and CKD. 254 
(76,86)  One other study by Raine et al (64) investigated the susceptibility of the uraemic 255 
heart to IRI and observed increased inosine release, a measure of ATP catabolism and thus 256 
indicative of enhanced myocyte damage.  In the study presented here, total global ischaemia 257 
in an ex vivo setting has been employed to assess ischaemic injury.  The consistent 258 
observation of enhanced susceptibility of the uraemic heart to IRI under these in vitro 259 
conditions confirms that this is a function of a uraemic cardiomyopathy, rather than purely a 260 
consequence of the in vivo uraemic milieu. 261 
The continuing responsiveness of cardiac metabolism to insulin in uraemia during in vitro 262 
perfusion (table 2) indicates that the increased susceptibility to IRI here is not a result of 263 
reduced metabolic flexibility. (2,26)  However, the lack of the cardioprotective effect of 264 
insulin (figure 1) and the alterations in Akt phosphorylation in uraemic hearts  (figures 5 and 265 
6) demonstrated in this study indicate that an underlying defect in the RISK pathway is more 266 
likely responsible. 267 
The lack of insulin mediated cardioprotection in uraemic hearts is in contrast to experimental 268 
studies on normal hearts and non-uraemic models of cardiac hypertrophy (37,67).  This 269 
therefore may be a unique finding of UCM.  However, Dikow et al (23) demonstrated a 270 
reduction in infarct size in uraemic hearts exposed to hyperinsulinaemic euglycaemic 271 
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clamping (for 45 minutes prior to ligation of the left anterior descending coronary artery and 272 
continued throughout ischaemia and reperfusion).  Two significant differences in study 273 
design may account for the apparent contradiction here.  Firstly, Dikow et al administered 274 
insulin prior to the ischaemic insult, in effect a pre-conditioning stimulus.  The protective 275 
effects of pre-conditioning and post-conditioning may be linked by the RISK pathway. (33)  276 
However, neither process is fully characterised and it is possible for aspects of the 277 
pre-conditioning pathway to remain effective while the post-conditioning pathway is not.  278 
Secondly, the concurrent administration of a significant glucose load can enhance myocardial 279 
glucose metabolism, an intervention known to be cardioprotective. (50)  However, both of 280 
these potential mechanisms should have improved the outcome in the control group, which 281 
was not the case, suggesting that in Dikow’s study cardioprotection was not conferred 282 
through previously identified mechanisms such as the RISK pathway. 283 
The cardio-protective effects of insulin have been widely studied utilising a range of cardiac 284 
preparations. (29,39,52,92)  Insulin has been shown to reduce cell death and improve 285 
function during the reperfusion period.  These effects are critically dependent on both Akt 286 
and GSK3β phosphorylation. (33,40)  The loss of insulin-mediated cardioprotection 287 
observed in the uraemic heart may therefore reflect impaired signalling through these key 288 
components of the RISK pathway.  In the absence of IRI, uraemia was associated with 289 
increased phospho Akt expression (figure 4).  While this might be predicted to be 290 
cardio-protective, the findings of Nagoshi et al (56) suggest that chronic activation of the 291 
RISK pathway can also lead to down regulation of key intermediates and a loss of the 292 
cardio-protective phenotype.  While the data presented here do not show a deficit in insulin 293 
stimulated phosphorylation of Akt or GSK3β in unfractionated cellular extracts, closer 294 
investigation of Akt isoform expression post-IRI suggests alterations in Akt2 expression 295 
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(figure 6).  DeBosch et al (21) have previously demonstrated that Akt 2 rather than Akt1 296 
underlies RISK-mediated cardioprotection.  Data here support the concept that insulin 297 
stimulation alters Akt2 expression post-IRI in control and uraemic hearts with an additional 298 
independent reduction in post-IRI levels of Akt2 in uraemic hearts.  Thus the Akt signalling 299 
axis is modified in the post-ischaemic uraemic heart raising the possibility of its involvement 300 
in the increased IRI susceptibility. 301 
Rosiglitazone therapy re-sensitised the uraemic heart to the cardio-protective effects of 302 
insulin.  In uraemic hearts rosiglitazone treatment improved functional recovery (RPP) at all 303 
time points in addition to all measures of function and efficiency.  The addition of insulin 304 
post IRI to rosiglitazone-treated hearts had an additive effect, achieving significant increases 305 
in RPP at all time points (figure 3 and table 5).  These results demonstrated that, despite the 306 
lack of effect of insulin alone, IRI damage in the uraemic heart is amenable to salvage by 307 
selected interventions, and further that rosiglitazone treatment is capable of ‘re-sensitising’ 308 
the uraemic heart to the pro-survival effects of insulin.  Rosiglitazone demonstrated modest 309 
pro-survival effects in control hearts in keeping with previous studies, (54) but did not 310 
provide addition benefit to insulin treatment alone (figure 2 and table 4).  This may represent 311 
a maximal effect as control hearts exposed to insulin at reperfusion are already achieving a 312 
recovery of RPP of approximately 85%. 313 
These results complement those of Taniguchi et al who have demonstrated pioglitazone 314 
mediated IRI cardioprotection in Otsuka Long-Evans Tokushima Fatty (OLETF) rats, a 315 
non-uraemic model on insulin resistance. (83)  They also identified pioglitazone mediated 316 
enhancement of stress induced Akt phosphorylation, suggesting that this is the likely path of 317 
action.  The re-sensitisation to the effects of insulin in the study presented here also suggests 318 
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that rosiglitazone is acting through the RISK-Akt pathway as has been demonstrated in other 319 
experimental models utilising both rosiglitazone and the related TZD, pioglitazone.  Yue et 320 
al (91), utilising diabetic rats and rosiglitazone administration as in this study, demonstrated 321 
rosiglitazone treatment conferred a similar degree of cardio-protection, with enhanced 322 
post-IRI Akt phosphorylation.  Cardioprotection and Akt phosphorylation were almost 323 
completely abolished by inhibition of the upstream RISK pathway intermediate 324 
phosphatidylinositol 3-kinase (PI3K), with Wortmannin.  Lie et al (48) demonstrated in 325 
hypercholesterolaemic rabbit hearts rosiglitazone-mediated reductions in post-IRI apoptosis, 326 
a well recognised effect of Akt activation, although that was not directly assessed in their 327 
study.  Cao et al (16) confirmed pioglitazone-mediated reductions in post-IRI cardiomyocyte 328 
apoptosis in the rat heart associated with reduced caspase 3 and Bax expression 329 
(pro-apoptotic) and increased Bcl-2 expression (anti-apoptotic), alterations normally 330 
associated with Akt activation. (38,63,88) 331 
More recently Yasuda et al (89) have demonstrated pioglitazone-mediated protection against 332 
in vivo myocardial infarction of rabbit hearts, linked to increased phospho Akt and phospho 333 
eNOS.  eNOS is a downstream target of Akt (28,52,81) and Akt mediated pro-survival 334 
effects are dependent on generation of NO. (28)  Protection was abrogated in Yasuda’s study 335 
by the application of inhibitors of PPARγ, PI3K and NOS inhibition, providing strong 336 
evidence for a TZD-PI3K-Akt-eNOS mediated mechanism of cardio-protection post IRI. 337 
There is a great clinical need to modify the functional consequences of UCM.  In the 338 
haemodialysis population in particular strategies to improve the tolerance of the heart to 339 
ischaemic insult are urgently required.  McIntyre et al have assessed cardiac function and 340 
damage during haemodialysis using serum troponin T concentrations, serial 341 
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echocardiography and serial positron emission tomography scans. (12,13,20)  They have 342 
demonstrated repeated episodes of myocardial ischaemia (myocardial stunning) and regional 343 
ventricular dysfunction associated with haemodialysis, and further, that the presence of such 344 
defects predicts deterioration of cardiac function in the subsequent 12 months. (12)  As 345 
haemodialysis is a predictable event it is amenable to prophylactic strategies, avoiding the 346 
pitfall of interventions for acute cardiac ischaemia when the protective intervention is often 347 
administered too late. (4)  Pre-treatment protective interventions have already been 348 
successful in other clinical situations, such as coronary artery bypass grafting and acute 349 
myocardial infarction (AMI). (14,35,44,60) 350 
Clinically rosiglitazone treatment has been associated with exacerbation of heart failure and 351 
an enhanced incidence of myocardial infarction in non-CKD populations. (9,32,42)  352 
However, as discussed above, pioglitazone also has experimental data to support a role in 353 
activation of the RISK pathway.  Furthermore, there is no excess risk of myocardial 354 
infarction or heart failure associated with its use in clinical practice. (30)  There is also 355 
theoretical reason to suspect clinically significant differences in outcomes in the end stage 356 
renal failure population, where the effects of rosglitazone on the distal tubule (41) will be 357 
diminished.  The safety of TZDs in renal failure has been tested in a number of post hoc or 358 
retrospective studies.  Schneider et al (70) performed a post hoc analysis of the PROactive 359 
trial and demonstrated reduced all-cause mortality, myocardial infarction and stroke in 360 
patients with CKD (GFR <60ml/min/1.73m2) treated with pioglitazone.  Subsequently 361 
Ramirez et al (65) demonstrated increased all-cause mortality in rosiglitazone treated patients 362 
on haemodialysis enrolled in the Dialysis Outcomes and Practice Patterns Study (DOPPS).  363 
Yet Brunelli et al (11) have shown reduced all-cause mortality for haemodialysis patients 364 
receiving either pioglitazone or rosiglitazone, with no significant difference between the two 365 
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agents.  The safety of TZDs in CKD therefore remains unclear. (8)  Rosiglitazone treatment 366 
in this study was utilised in a way previously shown to be cardio-protective in experimental 367 
IRI. (91)  The duration of treatment was too short to have a significant effect on cardiac 368 
hypertrophy.  However, a trend towards reduced cardiac function and a statistically 369 
significant increase in % lung water were noted (tables 1 and 3). 370 
These findings and the clinical data limit the direct ‘translatability’ of the positive findings in 371 
this study.  However, the core finding of successful improvement in functional outcomes in 372 
uraemic hearts after IRI should provoke further investigation of alternative protective 373 
strategies involving the Akt-eNOS pathway.  Many such alternatives have been investigated 374 
in non-uraemic models. (7,33)  Disappointingly the extensive pre-clinical data is not yet 375 
matched by corresponding success in clinical trials.  Adenosine or the synthetic Adenosine 376 
receptor agonist AmP579 have been examined in 3 clinical trials (45,53,68), the results of 377 
which are mixed and essentially flawed by aspects of study design (59).  However, complete 378 
re-analysis of the largest of these trials, AMISTAD-II, has shown benefit (reduced early and 379 
late survival, and reduced death or heart failure composite endpoint at 6 months) to the use of 380 
adenosine as an adjunct to reperfusion in acute myocardial infusion in those with a short 381 
duration of ischaemic symptoms. (44) 382 
Another alternative mechanism of RISK pathway activation with early positive outcomes in 383 
human studies is ‘ischaemic post-conditioning’, an extension of the original discovery by 384 
Murry et al (55) of reduce IRI after repeated episodes of brief ischaemia prior to the index 385 
ischaemic event (ischaemic pre-conditioning).  Ischaemic post-conditioning was first defined 386 
by Kin et al (43) and the mechanism has since been extensive studied and found to involve 387 
activation of the RISK pathway. (78)  Since 2005 there have been several translational 388 
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clinical studies demonstration significant reductions in infarct size and improved functional 389 
parameters when utilising ischaemic post-conditioning in the treatment of AMI. (19,80,84)  390 
However, the general utility of this method is limited by the need for access to the coronary 391 
circulation.  More attractive might be the concept of remote ischaemic conditioning, in 392 
which repeated brief ischaemia to an organ remote from the heart either pre-ischaemia, or 393 
pre-reperfusion, confers protection from IRI. (34,62)  Two human studies, one in human 394 
volunteers and patients with coronary artery disease (51) and one in the setting of acute 395 
myocardial infarction (14) have shown that repeated brief (5 minute) limb ischaemia, induced 396 
using an inflatable cuff, improve endothelial function and reduce infarct size following 397 
reperfusion.  Further, investigation is required to confirm these results, but the technique is 398 
attractive in instances of predictable IRI, such as haemodialysis. 399 
In an alternative approach significant cardio-protection in experimental and human studies 400 
has been demonstrated through inhibition of the final end effector of IRI, the mitochondrial 401 
permeability transition pore (mPTP). (5)  This large non-selective pore forms in the 402 
mitochondrial inner membrane during reperfusion resulting in cell death through, dissipation 403 
of the mitochondrial membrane potential, inhibition of ATP production, release of 404 
pro-apoptotic ligands and swelling and rupture of mitochondria.  Inhibition of mPTP 405 
opening is the primary effect through which RISK pathway activation reduces IRI. (17,36)  406 
The long established immunosuppressive drug cyclosporin A directly inhibits opening on the 407 
mPTP, and has previously been shown to be cardio-protective in experimental models. (73)  408 
Recently however, a small scale study has confirmed this effect in humans.  Piot et al 409 
demonstrated reduced infarct size with the use of a single bolus of cyclosporin prior to 410 
reperfusion in 58 patients undergoing primary percutaneous coronary intervention for acute 411 
myocardial infarction. (60) 412 
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Therefore, although TZDs may not be utilised in clinical practice as cardio-protective agents 413 
in renal failure, multiple other RISK pathway activating manoeuvres have been identified in 414 
experimental studies and there is a growing body of clinical evidence for their utility in the 415 
non-uraemic population.  Such avenues should be the focus of future studies in the CKD 416 
population. 417 
The reduction in HOMA-IR scores by rosiglitazone was reduced in uraemic animals.  418 
Overall rosiglitazone improved insulin sensitivity as evidenced by reduce HOMA-IR scores 419 
(table 1).  However, whilst exhibiting the same trend, this effect was not statistically 420 
significant in subgroup analysis of uraemic animals.  TZD treatment has previously been 421 
reported to have no effect on serum glucose and insulin concentrations in non-diabetic rats. 422 
(74)  However, rosiglitazone did significantly reduce HOMA-IR values in control animals in 423 
this model.  The lack of statistically significant effect in the uraemic group appears to stem 424 
from a dilution of the effect due to a additional non-significant trend for lower HOMA-IR 425 
values in ureamic animals. 426 
The metabolic and pleiotropic effects of insulin can be altered independently in CKD.  427 
Insulin resistance as it is typically attributed in clinical and experimental studies relates 428 
specifically to one of insulin’s many effects, namely that of serum glucose control.  Using 429 
this definition, insulin resistance, which remains an independent risk factor for cardiovascular 430 
death in CKD (6,75), has been implicated in the pathogenesis of pathological cardiac 431 
hypertrophy (24,69).  However, the data presented here clearly reveal resistance to the 432 
pleiotropic effects of insulin, in the absence of systemic metabolic insulin resistance.  This is 433 
consistent with data from Potenza et al (61)who have demonstrated defects in discrete 434 
pathways of the insulin signalling cascade which leave signal transduction unaffected through 435 
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other routes. 436 
Resistance to the metabolic effects of insulin results in hyperinsulinaemia, and imbalance in 437 
the various pleiotropic effects of insulin at the level of the endothelium, gene transcription 438 
and protein synthesis that favour cardiac hypertrophy (24,69).  In particular it appears that 439 
hyperinsulinaemia can exacerbate pathological cardiac hypertrophy in the presence of other 440 
factors.  This has been demonstrated in aortic banded rats (24), where the combination of 441 
hyperinsulinaemia and hypertension produced significantly more cardiac hypertrophy than 442 
hypertension alone.  Here we demonstrate that uraemia is associated with a ‘primary’ defect 443 
in one of the pleiotropic effects of insulin, independent of metabolic insulin resistance. 444 
Conclusions 445 
This is the first study to demonstrate significantly reduced function of the ex vivo uraemic 446 
heart after IRI.  Further, the loss of insulin mediated cardio-protection and alterations in Akt 447 
expression and phosphorylation suggest an underlying deficit in the RISK pathway. 448 
The insulin sensitising agent rosiglitazone restored the cardio-protective effects of insulin, in 449 
the uraemic heart. 450 
Enhanced IRI damage and pathological cardiac hypertrophy occurred in the absence of either 451 
systemic or cardiac ‘metabolic’ insulin resistance, despite the utility of insulin resistance as a 452 
risk factor for cardiovascular disease in the CKD. 453 
The role of the RISK pathway in the development of UCM and the cardio-protective 454 
potential of its manipulation warrant further investigation. 455 
456 
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Figures 782 
 783 
Figure 1: Recovery of cardiac function over time in control and uraemic hearts 784 
Upper panel: absolute rate pressure product (RPP) pre and post 25 minutes warm total global 785 
ischaemia.  Lower panel: recovery of RPP as a percentage of normoxic value.  Uraemic 786 
hearts exhibited poorer functional recovery after the ischaemic insult.  Insulin, which 787 
improved functional recovery in control hearts, failed to improve functional recovery in 788 
uraemic hearts.  *p<0.05 C-I vs. C+I; #p<0.05 C+I vs. U+I; §p<0.05 C-I vs. U-I.  All 789 
groups n=5 790 
 791 
Figure 2: Effect of insulin and rosiglitazone on recovery of RPP after ischaemia 792 
reperfusion injury in control hearts 793 
Mean ± SEM of % recovery of baseline rate pressure product (RPP) in control hearts after 794 
25min warm total global ischaemia.  -I: no insulin, +I: with insulin, -R: no rosiglitazone, +R: 795 
with rosiglitazone.  Rosiglitazone appeared to improve recovery post IRI in control hearts, 796 
but did not add any benefit to insulin treatment.  *p<0.05 -I-R vs. +I-R, §p<0.05 -I+R vs. 797 
+I+R.  C-I-R n=4; C+I-R n=5; C-I+R n=5; C+I+R n=5 798 
 799 
Figure 3: Effect of insulin and rosiglitazone on recovery of RPP after ischaemia 800 
reperfusion injury in uraemic hearts 801 
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Mean ± SEM of % recovery of baseline rate pressure product (RPP) in uraemic hearts after 802 
25min warm total global ischaemia.  -I: no inuslin, +I: with insulin, -R: no rosiglitazone, +R: 803 
with rosiglitazone.  Rosiglitazone and insulin treatment produced significant improvements 804 
in post IRI recovery greater than either therapy alone.  #p<0.05 +I-R vs. +I+R.  U-I-R n=4; 805 
U+I-R n=5; U-I+R n=5; U+I+R n=5 806 
 807 
Figure 4: Total and phospho Akt and GSK3β protein expression in control and uraemic 808 
hearts prior to ischaemia reperfusion injury 809 
Representative immunoblot of total and phospho Akt and GSK3β expression in uraemic and 810 
control hearts prior to either ischaemia or reperfusion.  Total Akt expression is unchanged 811 
between control and uraemic hearts.  However, phospho Akt expression is increased in 812 
uraemic hearts.  (relative optical density 1.00±0.08 vs. 1.3±0.11; n=12, p<0.05)  Total and 813 
phospho GSK3β remain unchanged in uraemic animals. 814 
 815 
Figure 5: Akt1 and Akt2 protein expression in control and uraemic hearts prior to 816 
ischaemia reperfusion injury 817 
Akt1 and Akt2 isoform expression in whole cell extracts determined by immuno-precipitation 818 
and immunoblotting.  The increase in overall pAkt expression in uraemic hearts (see text) 819 
related predominantly to pAkt2 expression, although this did not reach statistical 820 
significance.  A - Representative immunoblot of phospho and total Akt 1 and Akt 2 821 
expression in control and uraemic hearts.  B - Mean±SEM values of relative Akt1 and Akt2 822 
expression.  All values normalised to the respective control.  *p<0.05 uraemic vs. control; 823 
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Control n=10, Uraemic n=10 824 
 825 
Figure 6: Effect of uraemia and insulin on Akt1 and Akt2 phosphorylation post 826 
ischaemia reperfusion injury 827 
Akt1 and Akt2 isoform expression in whole cell extracts after 25min warm total global 828 
ischaemia determined by immuno-precipitation and immunoblotting.  Insulin produced 829 
increases in pAkt1 and pAkt2.  Both insulin and uraemia were associated with reduced Akt2 830 
expression post ischaemia.  A - Representative immunoblot of phospho and total Akt 1 and 831 
Akt 2 expression in control and uraemic hearts with and without insulin.  B - Mean±SEM 832 
values of relative Akt1 and Akt2 expression post IRI in the presence of absence of insulin.  833 
All values normalised to the respective control.  *p<0.05 vs.  no insulin; #p<0.05 vs. 834 
respective control; All groups n=5 835 
 836 
837 
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Tables 838 
Table 1: Effect of uraemia and rosiglitazone on renal function, anaemia, 839 
anthropometric measurements and serum metabolic substrate concentrations 840 
Mean±SEM values for serum urea, creatinine and haematocrit values, anthropometric 841 
measures and serum metabolic substrate concentrations in control and uraemic animals.  842 
Rosiglitazone had no significant effect on either renal function or cardiac hypertrophy but 843 
was associated with lower serum glucose and insulin concentrations, and thus HOMA-IR 844 
values.  No change was detected in serum free fatty acid concentrations.  C-R:  control - 845 
rosiglitazone, C+R: control + rosiglitazone, U-R: uraemic - rosiglitazone, U+R: uraemic + 846 
rosiglitazone.  p values given for two way ANOVA; subgroup analysis by Scheffé post hoc 847 
test.  §p<0.05 vs. no rosiglitazone; #p<0.05 vs. respective control; a - C-R n=8, C+R n=10, 848 
U-R n=9, U+R n=10; b - C-R n=5, C+R n=7, U-R n=7, U+R n=6 849 
Table 2: Effect of uraemia and insulin on in vitro baseline cardiac function, efficiency 850 
and metabolism in control and uraemic hearts 851 
Mean±SEM values for measures of cardiac function and relative substrate contribution of 852 
Acetyl-CoA to the Krebs cycle in control and uraemic hearts perfused in the absence or 853 
presence of insulin.  Uraemia was not associated with decline in measures of cardiac 854 
function.  Insulin acted to increase cardiac contractility (dP/dt) and efficiency, independently 855 
of uraemia.  Uraemia was associated with a significant shift from fatty acid to carbohydrate 856 
metabolism, yet substrate selection remained sensitive to insulin.  C-I - Control no insulin; 857 
U-I - Uraemic no insulin; C+I - Control plus insulin; U+I - Uraemic plus insulin.  p values 858 
given for two way ANOVA;  subgroup analysis by Scheffé post hoc test, *p<0.05 vs. no 859 
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insulin; #p<0.05 vs. respective control 860 
 861 
Table 3: Effect of rosiglitazone on in vitro baseline cardiac function 862 
Mean±SEM for rate pressure product (RPP), contractility (dP/dtmax), relaxation (dP/dtmin), 863 
myocardial oxygen consumption (MVO2) and efficiency in control and uraemic animals ± 864 
rosiglitazone therapy prior to ischaemia reperfusion.  C-R:  control - rosiglitazone, C+R: 865 
control + rosiglitazone, U-R: uraemic - rosiglitazone, U+R: uraemic + rosiglitazone.  p 866 
values given for two way ANOVA; subgroup analysis by Scheffé post hoc test.  a - C-R n=8, 867 
C+R n=10, U-R n=6, U+R n=10 868 
 869 
Table 4: Effect of insulin and rosiglitazone on maximal recovery of control hearts after 870 
ischaemia reperfusion injury 871 
Mean ± SEM of maximal % recovery of baseline cardiac function in control hearts after 872 
25min warm total global ischaemia.  -I: no inuslin, +I: with insulin, -R: no rosiglitazone, +R: 873 
with rosiglitazone.  *p<0.05 -I-R vs. +I-R, §p<0.05 -I+R vs. +I+R. 874 
 875 
Table 5: Effect of insulin and rosiglitazone on maximal recovery of uraemic hearts after 876 
ischaemia reperfusion injury 877 
Mean ± SEM of maximal % recovery of baseline cardiac function in uraemic hearts after 878 
25min warm total global ischaemia.  -I: no inuslin, +I: with insulin, -R: no rosiglitazone, +R: 879 
with rosiglitazone.  #p<0.05 +I-R vs. +I+R 880 
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   p value 
 C-R 
(n=10) 
C+R 
(n=15) 
U-R 
(n=10) 
U+R 
(n=15) 
 C vs. U -R vs. +R
Weight gain (g) 268±13 266±9 266±15 253±12  ns ns 
Tibia length (cm) 4.48±0.03 4.47±0.03 4.51±0.04 4.48±0.02  ns ns 
Heart weight (g) 1.57±0.04 1.56±0.08 1.79±0.08# 1.80±0.53#  <0.05 ns 
HW:TL (g/cm) 0.35±0.01 0.35±0.02 0.40±0.02 0.40±0.01#  <0.05 ns 
% Lung water 75.8±0.3 76.7±0.5 76.4±0.3 76.9±0.1  ns <0.05 
Left kidney (g) 1.40±0.08 1.46±0.04 1.55±0.08 1.54±0.09  ns ns 
Liver (g) 15.2±1.3 13.1±0.9 14.0±1.1 12.8±0.6  ns ns 
        
Urea (mM) 4.6±0.5 4.9±0.4 11.5±1.1# 13.3±1.1#  <0.05 ns 
Creatinine (µmol/l) 28.9±2.3 29.0±1.1 71.6±6.5# 75.0±9.3#  <0.05 ns 
Hct (%) 41±1 41±1 35±1# 35±1#  <0.05 ns 
Glucose (mM)a 8.4±0.6 6.2±0.4§ 7.2±0.5 5.9±0.5  ns <0.05 
Insulin (µg/l)b 1.33±0.32 0.89±0.17 1.07±0.13 0.89±0.2 6  ns ns 
HOMA-IR (mmol/L x µU/ml)b 12.1±2.3 6.4±1.4§ 8.6±1.5 6.3±2.2  ns <0.05 
Free fatty acids (mM) 0.31±0.04 0.36±0.04 0.32±0.05 0.35±0.05  ns ns 
 
       p value 
 C-I 
(n=8) 
U-I 
(n=8) 
C+I 
(n=6) 
U+I 
(n=8) 
 C vs. U -I vs. +I 
RPP x103 (mmHg.min) 45±3 49±2 45±5 51±3  ns ns 
dP/dtmax (mmHg/s) 4480±756 5426±561 5960±400 6579±368  ns <0.05 
dP/dtmin (mmHg/s) -2929±160 -3131±142 -3127±216 -3566±193  ns <0.05 
MVO2 (µmol/g/min) 0.85±0.06 0.82±0.06 0.65±0.10 0.65±0.06  ns ns 
Efficiency x104 (mmHg/µmol/g wet wt)  5.4±0.4 6.4±.07 7.6±1.0 8.3±0.9  ns <0.05 
        
Glucose (%) 10.6±1.2 12.9±1.8 12.3±0.3 17.3±1.4*#  <0.05 <0.05 
Palmitate (%) 48.8±2.1 37.8±2.2# 31.4±1.8* 16.1±0.9*#  <0.05 <0.05 
Unlabelled (%) 40.6±1.9 49.3±2.2# 56.3±1.9* 66.6±1.9*#  <0.05 <0.05 
 
       p value 
 C-R 
(n=9) 
C+R 
(n=10) 
U-R 
(n=9) 
U+R 
(n=10) 
 C vs. U -R vs. +R
RPP x 103 (mmHg.min) 30.1±1.9 28.1±1.7 32.5±1.4 29.1±1.5  ns ns 
dP/dtmax (mmHg/s) 3371±217 3122±238 3402±234 3074±204  ns ns 
dP/dtmin (mmHg/s) -1926±87 -1903±101 -2002±81 -1856±66  ns ns 
MVO2 (µmol/g/min)a 0.93±0.05 0.95±0.03 0.98±0.03 0.93±0.04  ns ns 
Efficiency x 103 (mmHg/µmol/g)a 32.1±2.4 29.9±1.8 33.8±1.8 31.6±1.8  ns ns 
 
       p value 
 C-I-R 
(n=4) 
C+I-R 
(n=5) 
C-I+R 
(n=5) 
C+I+R 
(n=5) 
 -I vs. +I -R vs. +R
RPP (% recovery) 35.5±10.4 85.9±14.4* 57.0±19.5 90.0±17.6  <0.05 ns 
dP/dtmax (% recovery) 34.4±8.1 65.9±24.5 55.9±19.2 87.7±17.8§  ns ns 
dP/dtmin (% recovery) 70.0±20.8 79.1±24.6 65.6±23.4 93.2±20.5  ns ns 
MVO2 (µmol/g/min) 0.91±0.01 0.94±0.08 0.98±0.03 0.89±0.04  ns ns 
Cardiac Efficiency (% recovery) 36.4±12.4 82.3±12.3 57.1±19.6 83.0±17.1  <0.05 ns 
 
       p value 
 U-I-R 
(n=4) 
U+I-R 
(n=5) 
U-I+R 
(n=5) 
U+I+R 
(n=5) 
 -I vs. +I -R vs. +R
RPP (% recovery) 11.5±6.2 12.7±7.0 46.2±19.2 61.8±15.9#  ns <0.05 
dP/dtmax (% recovery) 22.0±5.8 42.5±17.1 31.0±25.6 62.1±16.9#  ns ns 
dP/dtmin (% recovery) 9.5±3.5 27.6±7.9 50.7±20.1 70.7±17.6#  ns <0.05 
MVO2 (µmol/g/min) 0.80±0.07 0.83±0.02 0.86±0.03 0.94±0.07  ns ns 
Cardiac Efficiency (% recovery) 15.8±9.4 15.8±8.8 47.3±19 65.2±15.4#  ns <0.05 
 
